Heidelberg Pharma AG
WILEX AG: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement
DGAP-News: WILEX AG / Key word(s): Alliance PRESS RELEASE WILEX AG: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement Munich, Germany, 25 January 2017 – WILEX AG (ISIN DE000A11QVV0 / WL6 / FWB) today announced that its subsidiary Heidelberg Pharma GmbH, Ladenburg, Germany, signed the license agreement with the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) in Berlin covering BCMA antibodies. The license agreement follows an option agreement signed in September 2016. Financial details are confidential but will not have a material impact on WILEX’ cash reach. As a result of a selection and optimization process of the BCMA antibodies, the ATAC candidate HDP-101 was selected and is currently being prepared for clinical development that could start by the end of 2018. Related releases 24 January 2017: Am MDC entwickelte Tumor-Antikörper gegen Knochenmarkkrebs gehen in die Anwendung (in German only) 19 September 2016: WILEX AG: Subsidiary Heidelberg Pharma Signs Option Agreement with Max Delbrück Center About Max Delbrück Center About Heidelberg Pharma’s proprietary ATAC technology About WILEX and Heidelberg Pharma
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
25.01.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | WILEX AG |
Grillparzerstr. 18 | |
81675 München | |
Germany | |
Phone: | +49 (0)89 41 31 38 – 0 |
Fax: | +49 (0)89 41 31 38 – 99 |
E-mail: | info@wilex.com |
Internet: | www.wilex.com |
ISIN: | DE000A11QVV0 |
WKN: | A11QVV |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |